Mottola Frank
Insider CIK 1804567 · SUPN Sr VP, Quality, GMP Oper. & IT
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2026-10-30 | 2026-11-02 | 100,000 | — | $0 | 100,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2026-08-12 | 2026-08-14 | 1,650 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2026-08-12 | 2026-08-14 | 797 | $46.57 | $37.1K | 19,544 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2026-08-12 | 2026-08-14 | 1,650 | — | $0 | 20,341 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2026-08-12 | 2026-08-14 | 1,650 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2026-08-12 | 2026-08-14 | 797 | $46.57 | $37.1K | 19,544 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2026-08-12 | 2026-08-14 | 1,650 | — | $0 | 20,341 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2026-07-29 | 2026-07-31 | 1,650 | — | $0 | 1,650 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2026-07-29 | 2026-07-31 | 1,650 | — | $0 | 1,650 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2026-03-09 | 2026-03-10 | 1,623 | $53.65 | $87.1K | 18,440 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2026-03-06 | 2026-03-10 | 3,750 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2026-03-06 | 2026-03-10 | 3,750 | — | $0 | 21,856 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2026-03-06 | 2026-03-10 | 1,793 | $54.73 | $98.1K | 20,063 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2026-02-28 | 2026-03-03 | 3,750 | — | $0 | 3,750 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2026-02-25 | 2026-02-26 | 1,875 | — | $0 | 1,875 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2026-02-25 | 2026-02-26 | 1,875 | — | $0 | 19,083 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2026-02-25 | 2026-02-26 | 977 | $50.69 | $49.5K | 18,106 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2026-02-24 | 2026-02-25 | 750 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2026-02-24 | 2026-02-25 | 1,125 | — | $0 | 3,375 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2026-02-24 | 2026-02-25 | 1,250 | — | $0 | 2,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2026-02-24 | 2026-02-25 | 603 | $51.35 | $31.0K | 16,246 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2026-02-24 | 2026-02-25 | 750 | — | $0 | 16,996 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2026-02-24 | 2026-02-25 | 1,125 | — | $0 | 16,849 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2026-02-24 | 2026-02-25 | 670 | $50.86 | $34.1K | 17,208 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2026-02-24 | 2026-02-25 | 1,250 | — | $0 | 17,878 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2026-02-24 | 2026-02-25 | 368 | $50.86 | $18.7K | 16,628 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2026-02-18 | 2026-02-20 | 3,000 | — | $0 | 3,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2026-02-18 | 2026-02-20 | 13,500 | — | $0 | 13,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2025-12-19 | 2025-12-22 | 5,000 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2025-12-19 | 2025-12-22 | 15,000 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2025-12-19 | 2025-12-22 | 15,000 | $25.30 | $379.5K | 30,496 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2025-12-19 | 2025-12-22 | 5,000 | $39.40 | $197.0K | 20,496 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2025-12-19 | 2025-12-22 | 5,000 | $50.22 | $251.1K | 15,496 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2025-12-19 | 2025-12-22 | 15,000 | $50.47 | $757.0K | 15,496 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2025-09-12 | 2025-09-15 | 5,000 | — | $0 | 5,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2025-09-12 | 2025-09-15 | 5,000 | $45.87 | $229.3K | 15,496 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2025-09-12 | 2025-09-15 | 5,000 | $39.40 | $197.0K | 20,496 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2025-08-25 | 2025-08-27 | 14,000 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2025-08-25 | 2025-08-27 | 14,000 | $44.51 | $623.1K | 15,496 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2025-08-25 | 2025-08-27 | 14,000 | $12.98 | $181.7K | 29,496 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2025-03-07 | 2025-03-07 | 2,625 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2025-03-07 | 2025-03-07 | 1,356 | $39.11 | $53.0K | 15,151 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2025-03-07 | 2025-03-07 | 2,625 | — | $0 | 16,507 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2025-03-05 | 2025-03-05 | 610 | $33.05 | $20.2K | 14,827 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2025-03-05 | 2025-03-05 | 945 | $33.05 | $31.2K | 13,882 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2025-03-05 | 2025-03-05 | 337 | $33.05 | $11.1K | 15,437 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2025-02-26 | 2025-02-26 | 2,010 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2025-02-26 | 2025-02-26 | 3,750 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2025-02-26 | 2025-02-26 | 2,010 | — | $0 | 14,909 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2025-02-26 | 2025-02-26 | 976 | $39.48 | $38.5K | 13,933 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2025-02-26 | 2025-02-26 | 3,750 | — | $0 | 17,683 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2025-02-26 | 2025-02-26 | 1,909 | $39.48 | $75.4K | 15,774 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2025-02-23 | 2025-02-24 | 1,875 | — | $0 | 3,750 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2025-02-23 | 2025-02-24 | 1,875 | — | $0 | 12,899 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2025-02-22 | 2025-02-24 | 750 | — | $0 | 750 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2025-02-22 | 2025-02-24 | 1,250 | — | $0 | 3,750 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2025-02-22 | 2025-02-24 | 750 | — | $0 | 9,774 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2025-02-22 | 2025-02-24 | 1,250 | — | $0 | 11,024 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2025-02-21 | 2025-02-24 | 1,125 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2025-02-21 | 2025-02-24 | 1,125 | — | $0 | 9,576 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2025-02-21 | 2025-02-24 | 552 | $39.15 | $21.6K | 9,024 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2025-02-19 | 2025-02-21 | 20,000 | — | $0 | 20,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2025-02-19 | 2025-02-21 | 4,500 | — | $0 | 4,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2025-02-17 | 2025-02-19 | 2,625 | — | $0 | 2,625 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2025-02-05 | 2025-02-06 | 2,010 | — | $0 | 2,010 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2025-02-05 | 2025-02-06 | 3,750 | — | $0 | 3,750 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2025-01-28 | 2025-01-29 | 1,125 | — | $0 | 1,125 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2024-11-07 | 2024-11-08 | 15,000 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2024-11-07 | 2024-11-08 | 15,000 | $36.98 | $554.7K | 8,200 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2024-11-07 | 2024-11-08 | 15,000 | $9.13 | $136.9K | 23,200 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2024-02-28 | 2024-02-29 | 990 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2024-02-28 | 2024-02-29 | 460 | $27.94 | $12.9K | 7,779 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2024-02-28 | 2024-02-29 | 990 | — | $0 | 8,239 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2024-02-23 | 2024-02-27 | 1,875 | — | $0 | 5,625 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2024-02-23 | 2024-02-27 | 1,875 | — | $0 | 8,186 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2024-02-23 | 2024-02-27 | 937 | $29.06 | $27.2K | 7,249 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2024-02-22 | 2024-02-26 | 750 | — | $0 | 1,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2024-02-22 | 2024-02-26 | 990 | — | $0 | 990 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2024-02-22 | 2024-02-26 | 25,000 | — | $0 | 25,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2024-02-22 | 2024-02-26 | 5,000 | — | $0 | 5,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2024-02-22 | 2024-02-26 | 750 | — | $0 | 6,646 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2024-02-22 | 2024-02-26 | 335 | $27.94 | $9.4K | 6,311 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2023-11-14 | 2023-11-16 | 2,000 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2023-11-14 | 2023-11-16 | 2,000 | $9.24 | $18.5K | 6,791 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2023-11-14 | 2023-11-16 | 1,110 | $28.13 | $31.2K | 5,681 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | S Sale | 2023-03-14 | 2023-03-16 | 4,780 | $35.99 | $172.0K | 4,737 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2023-02-23 | 2023-02-27 | 30,000 | — | $0 | 30,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2023-02-23 | 2023-02-27 | 7,500 | — | $0 | 7,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2023-02-22 | 2023-04-12 | 750 | — | $0 | 2,250 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2023-02-22 | 2023-04-12 | 289 | $38.57 | $11.1K | 9,228 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2023-02-22 | 2023-04-12 | 750 | — | $0 | 9,517 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | D To issuer deriv | 2023-02-22 | 2023-02-24 | 750 | — | $0 | 2,250 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award | 2023-02-22 | 2023-02-24 | 750 | — | $0 | 9,517 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise deriv | 2023-02-16 | 2023-02-21 | 1,500 | — | $0 | 0 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | M Exercise | 2023-02-16 | 2023-02-21 | 1,500 | — | $0 | 8,944 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | F Tax w/h | 2023-02-16 | 2023-02-21 | 753 | $38.74 | $29.2K | 8,191 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2023-01-12 | 2023-01-17 | 1,500 | — | $0 | 1,500 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2022-02-22 | 2022-02-24 | 18,000 | — | $0 | 18,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2022-02-22 | 2022-02-24 | 3,000 | — | $0 | 3,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2022-02-22 | 2022-02-25 | 18,000 | — | $0 | 18,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2022-02-22 | 2022-02-25 | 3,000 | — | $0 | 3,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2021-02-19 | 2021-02-23 | 17,000 | — | $0 | 17,000 | SEC↗ |
| SUPN SUPERNUS PHARMACEUTICALS, | A Award deriv | 2020-02-21 | 2020-02-25 | 22,000 | — | $0 | 22,000 | SEC↗ |